Ginkgo Bioworks Holdings, Inc. has also added expertise across its biopharma team, including the appointment of Dr. Behzad Mahdavi, senior vice president of biopharma manufacturing & life science tools.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.354 USD | +22.03% |
|
+13.90% | -79.20% |
02:27pm | Ginkgo Bioworks Partners With Syngenta Crop Protection for new Biologicals | MT |
07-09 | Goldman Sachs Adjusts Price Target on Ginkgo Bioworks to $0.30 From $0.80, Maintains Sell Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-79.20% | 646M | |
+24.99% | 46.56B | |
+45.38% | 41.67B | |
+0.19% | 41.16B | |
+33.14% | 32.4B | |
+20.93% | 28.18B | |
-6.35% | 28.1B | |
+48.82% | 14.52B | |
+47.12% | 13.74B | |
+3.28% | 12.17B |
- Stock Market
- Equities
- DNA Stock
- News Ginkgo Bioworks Holdings, Inc.
- Ginkgo Bioworks Holdings, Inc. Appoints Behzad Mahdavi, Senior Vice President of Biopharma Manufacturing & Life Science Tools